Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
20h
Vaxcyte’s Strong Market Position and Financial Health Justify Buy Rating with $153 Target
Leerink Partners analyst David Risinger reiterated a Buy rating on Vaxcyte (PCVX – Research Report) on November 5 and set a price target ...
10h
Strong Q3 Performance and Future Growth Prospects Justify Buy Rating on Sarepta Therapeutics
William Blair analyst Sami Corwin has maintained their bullish stance on SRPT stock, giving a Buy rating today. Sami Corwin’s rating is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
3 charged in Payne's death
Biden addresses nation
Fed cuts interest rates
Trump picks chief of staff
Germany arrests US citizen
Navy fires ethics leader
Jury deliberations begin
Wins in Pennsylvania
Newsom calls special session
43 monkeys escape SC lab
Ellison begins 2-yr sentence
Jackson mayor indicted
Fired by Philadelphia Union
Flips PA Senate seat
9/11 plea deals revived
Snow back on Mount Fuji
Nissan to cut 9,000 jobs
NYC hotel fraud ruling
Giuliani appears in court
Volcano erupts in Indonesia
Arctic oil refuge plan
Nearly 1 in 6 adults diabetic
Pledges 'orderly' transition
Facebook shareholder suit
Wholesale inventories fall
Weekly jobless claims rise
Time to get flu, COVID shots
Mortgage rates rise again
New Pompeii DNA evidence
Expands bird flu testing
AU plans social media ban
Project Veritas suit revived
Feedback